Related Experiment Video
Updated: Jun 24, 2026

Preclinical Positron Emission Tomography with Body Conforming Animal Molds for Cloud-Based Automated Image Analysis in Mice
Published on: October 25, 2024
AMT: preclinical pharmacology studies
Faiz Niazi1, Joachim Drevs, Klaus Diergarten
1Auron Healthcare GmbH, 79100 Freiburg, Germany.
Abstract:
Auron-Misheil-Therapy (AMT) consisting of aqueous camomile extract supplemented with calcium, vitamins, the antihistamine chlorpheniramine and human insulin is under development as anti-cancer treatment. AMT was preclinically investigated in tumour cell lines and tumour xenografts to guide clinical phase I/II studies. AMT was tested against 56 human tumour cell lines, in a clonogenic assay in 98 patient-derived xenografts and in in vivo studies. AMT showed in vitro cytotoxic activity with highest susceptibility in cervical cancer, glioblastoma and colon cancers. In the clonogenic assay, anti- cancer activity of AMT was most active in cervical and uterine tumours, in colon cancer, glioblastoma, leukaemia, melanoma and pancreatic cancer. In vivo, AMT showed slight activity in tumour xenograft models of colon and mammary cancer. It also showed immune stimulatory effects by induction of IL-6- and TNF-alpha secretion in human PBMCs. The immune stimulatory potential of AMT, together with slight anti-tumour efficacy observed in the present study, indicates a role of AMT in tumour therapy.
Related Concept Videos
Preclinical Development: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Drug Discovery: Overview
Toxicity Testing in Animals
Bioavailability Study Design: Single Versus Multiple Dose Studies

